Skip to main content

Table 2 Uni- and multivariable analyses with the logistic regression

From: The value of the tumour-stroma ratio for predicting neoadjuvant chemoradiotherapy response in locally advanced rectal cancer: a case control study

  Univariable analysis Multivariable analysis
OR (95% CI) P AOR (95% CI) P
Age (year, mean ± SD) 0.99 (0.97–1.01) 0.505   
Sex
 Male Ref    
 Female 0.81 (0.46–1.42) 0.458   
Histopathological type
 Adenocarcinoma Ref    
 Mucinous adenocarcinoma 1.42 (0.42–4.85) 0.575   
Differentiation grade
 Well or moderate Ref    
 Poor 2.19 (0.69–7.01) 0.185   
cT status
 cT2 Ref    
 cT3 1.02 (0.28–3.76) 0.971   
 cT4 0.78 (0.20–3.04) 0.722   
cN status
 cN0 Ref    
 cN1 1.15 (0.54–2.42) 0.715   
 cN2 2.03 (0.96–4.30) 0.065   
Tumour location
 < 5 cm Ref    
 5–10 cm 0.83 (0.50–1.40) 0.491   
 > 10 cm 0.97 (0.16–6.00) 0.974   
CEA level
 Normal Ref    
 Abnormal 0.88 (0.53–1.47) 0.636   
CA199 level
 Normal Ref    
 Abnormal 1.28 (0.68–2.40) 0.450   
Time interval between nCRT and surgery
 < 7 weeks Ref    
 7–10 weeks 2.74 (0.79–9.56) 0.113   
 > 10 weeks 3.94 (1.16–13.4) 0.028   
Chemotherapeutic regimen
 5-fluorouracil Ref   Ref  
 Capecitabine 0.52 (0.19–1.40) 0.194 0.45 (0.16–1.28) 0.134
 FOLFOX 2.68 (1.27–5.68) 0.010 2.93 (1.33–6.46) 0.007
 Other regimens 1.36 (0.51–3.61) 0.541 1.53 (0.55–4.28) 0.415
Neoadjuvant radiotherapy dose
 < 45 Gy Ref   Ref  
 ≥ 45 Gy 3.71 (1.38–10.0) 0.006 5.25 (1.84–14.9) 0.002
TSR (three categery)
 Low Ref   Ref  
 Intermediate 0.60 (0.32–1.14) 0.121 0.45 (0.22–0.90) 0.025
 High 0.40 (0.21–0.76) 0.005 0.32 (0.16–0.65) 0.002
  1. Abbreviation: TSR tumour-stroma ratio